Heuson J C, Leclercq G
Arch Geschwulstforsch. 1975;45(5):417-22.
Using evidences of estrogen receptors in mammary tumor tissues it was tried 1. to find substances which inhibit the tumor growth by their binding to the estrogen receptors; 2. to predict responsiveness to endocrine therapy; and 3. to find a definition of an improved therapeutic strategy in breast cancer. There is a continuously increasing rate of receptor positive tumors, caused by an improved technique of determination and tissue handling. Estrogen receptors were detected in 73 per cent of all primary mammary tumors and 58 per cent of metastatic tumors respectively. As new therapeutic substances nafoxidine and Estracyt were tested in controlled clinical trials. To get exact data about hormonal sensitivity further quantitative investigations of receptor activities of mammary tumors and their therapeutical responsiveness have to be done. As a new step in the strategy of breast cancer therapy based on receptor determinations a combined therapy with hormones and cytotoxic chemotherapeutics has to be checked in clinical trials in uture.
利用乳腺肿瘤组织中雌激素受体的证据，人们试图：1. 寻找通过与雌激素受体结合来抑制肿瘤生长的物质；2. 预测对内分泌治疗的反应性；3. 找到改善乳腺癌治疗策略的定义。由于测定和组织处理技术的改进，受体阳性肿瘤的发生率持续上升。在所有原发性乳腺肿瘤和转移性肿瘤中，分别有73%和58%检测到雌激素受体。作为新的治疗物质，己烯雌酚和依西美坦在对照临床试验中进行了测试。为了获得有关激素敏感性的确切数据，必须对乳腺肿瘤的受体活性及其治疗反应性进行进一步的定量研究。作为基于受体测定的乳腺癌治疗策略的新步骤，激素与细胞毒性化疗药物的联合治疗必须在未来的临床试验中进行检验。
